Q1 2021 financial results

On May 11, we announce our financial results for the first quarter of 2021. Follow the investor presentation at 13:00pm CET or 7:00am US/EDT on the day. Find dial-in details and webcast link in our investor section.

This is Lundbeck

We are one of the only pharmaceutical companies in the world focusing exclusively on brain diseases, and we’re set apart by our specialization.

With more than 70 years of neuroscience expertise, Lundbeck has developed and commercialized some of the world's most widely prescribed therapies for brain diseases.

a better life for people with brain diseases

At Lundbeck, we see patients as people and are committed to support the person behind the disease.

LATEST NEWS

03 May, 2021 Press Release
New study finds that vortioxetine helps patients with MDD and comorbid Generalized Anxiety Disorder
03 May, 2021 Press Release
Nyt studie viser, at vortioxetin hjælper patienter med svær depression og komorbid generaliseret angst
22 April, 2021 Press Release
Vortioxetine significantly improves overall functioning in a global real-world study in Major Depressive Disorder

Come join us in making a difference to patients worldwide.

Job Opportunities

Explore the latest financial developments at Lundbeck.

Mohammad Sohail on working at Lundbeck

Cross-Cultural Leadership

See All Stories

Lundbeck at a glance

100

countries where our products are sold

5,600

employees supporting our purpose

1915

year Lundbeck was founded